BR+A Consulting Engineers’ Post

75 Years of medical innovation…👍

Medtech - A hidden gem? Yes it is, according to Carl Borrebaeck and the panel he moderated at Day 1 of BioStock Life Science Summit. The discussion highlighted key criteria for investing in medtech companies, including IP, business models, reimbursement strategies and regulatory pathways. A big thank you to: Karin Leire, Segulah Medical Acceleration Fiona Law, Potter Clarkson Magnus Holm, Peppermint Venture Partners GmbH Hanna Sjöström, Neola Medical

The Swiss HLG 2024 conference starts in beautiful Montreux on Sunday evening. We are thrilled to have Ed Saltzman, Senior Strategic Advisor at Lumanity as Key Note speaker. I caught up with Ed on his Key Note last night and his analysis and insights blew my mind - conference attendees are in for a real treat. Ed's topic is: Biopharma dealmaking: Time for a Rethink?   Biotechs have to accomplish two overarching goals to achieve a lucrative licensing deal with large pharma: 1) move their products through multiple stages of clinical and regulatory de-risking and; 2) demonstrate that these products have substantial revenue potential (now $1bn or more). Most pre-commerical biotechs continue to prioritize the first goal, but in today’s dynamic and volatile commercial environment, especially in the US, most fail to secure deals because they cannot make a compelling case that their asset can deliver on the second one. In 2009 when capital to fund development though PoC de-risking was scarce, Ed proposed a new value-driving concept for sellers: Proof of Relevance (PoR). PoR is a less capital intensive and faster route to de-risking assets prior to traditional PoC, by making a compelling case for an asset’s therapeutic and thus commercial value. By focusing only on clinical and regulatory de-risking, sellers were missing this opportunity.   Despite recent very challenging capital markets, a record number of companies have raised sufficient capital to move past PoC. Unfortunately, this has led to the value of establishing PoR being overlooked. The result is a surplus of clinically de-risked assets weighed down by unattractive commercial risk profiles.   Pharma perceives only a minority of assets to have the inherent, compelling commercial prospects needed to pass minimum revenue thresholds. These “corner property” assets are the basis of today’s mega-deals. However, the reality is that the vast majority of biotechs with post-POC assets are unlikely to achieve any large pharma deal unless PoR is as compelling as PoC.   In his Key Note talk, Ed will share his thoughts on how biotechs can best address this critical challenge, followed by discussion and Q&A led by Nigel Sheail of Versant Ventures. It's not too late to register and hear Ed's insights, please register here ➡ https://lnkd.in/daxgmUHa You can now find Ed's presentation here: https://lnkd.in/gH5wAUQ6 #swisshlg #biopharma #dealmaking #innovation #networking

CNY Biotech Accelerator, Upstate Medical University’s Medical Device Innovation Challenge (MDIC) is a 6-month virtual program mentoring selected early-to-mid stage start-up companies each year. The MDIC serves as a complementary and collaborative initiative to assist teams in preparation for incubation programs, expand their innovation ecosystem, and assess strategic planning by providing mentorship, resources, funding/pitch opportunities, and connections. To date, 42 teams have participated in MDIC since its inception in 2017 and have achieved impressive milestones during and after graduation. Learn more now >> https://lnkd.in/dyD-4S-R

Science2Medicine iNNvest is an initiative by Novo Nordisk , specifically designed to bridge the gap between scientific discoveries and real-world medical applications. It aims to support and invest in early-stage biotech and life sciences companies that focus on translating innovative research into practical therapies and medical solutions. Through Science2Medicine iNNvest, Novo Nordisk provides not only capital but also strategic guidance, leveraging their expertise in the life sciences sector to help these companies move from the research phase to commercial success. This initiative is a key part of Novo Nordisk' mission to accelerate the journey from science to medicine, fostering innovation that can improve patient outcomes. watch the video from LSX - partnering for Life Science eXecutives where Neil Anderson explains it all!

Innovo Research is excited to announce that Collom & Carney Clinic has joined the Innovo Research Network. With 11 community-based locations, 20+ specialties, and over 100 providers, Collom & Carney brings incredible expertise and reach to our mission of expanding clinical trial accessibility. Their commitment to value-based care and innovation aligns perfectly with our vision for the future of clinical research. Welcome to the network, Collom & Carney! Read more about this partnership: https://lnkd.in/gMEb8EGh

Medilink North of England have launched a two-fold event for life science companies in our region, aiming to tackle the challenges of finding development funding and commercialising their new, ground-breaking ideas and innovations, hosted by RBC Brewin Dolphin in Newcastle. Our Business Angel Activation session was specifically aimed at demonstrating to local clinicians, surgeons and medical researchers the benefits of becoming a Business Angel through investing in new medical innovations. Immediately following this, Medilink’s Investment Pitching Competition provided an opportunity for seven life sciences companies from across the North of England, each with exciting new medical innovations, to pitch for investment to a group of new and existing business angels and investors. The seven successful companies selected to pitch were: Kerato Limited , Flomark Ltd, Viveca Biomed, Sapien View, NunaBio Limited, ClotProtect Therapeutics and ESP Diagnostics Limited. Read more here: 👉 https://lnkd.in/dN4BvFnx RBC Brewin Dolphin | British Business Bank | Hill Dickinson LLP| Newcastle University | The North East Fund Ltd. | Northstar Ventures UK | UK Business Angels Association

A new chapter for DIESSE begins today.   Today Fremman Capital has announced the acquisition of a majority stake in DIESSE Diagnostica Senese.   Fremman recognizes DIESSE as a company with significant potential for international expansion and is willing to enhance its leadership position in the market.   Our CEO M. Boggetti is glad to announce “Over the past five years, we have invested more than 10% of our revenues in research and development, focusing on innovation in immune system diagnostics. With Fremman's contribution, we aim to widely disseminate this innovation in the coming years, helping patients worldwide achieve better diagnoses and more effective treatments”.

hVIVO PLC (AIM:HVO) has taken a big step towards its goal of reaching £100 million in revenue by 2028 with the acquisition of two clinical research units in Germany for £8.4 million (€10 million) from Clinical Research Services Management (CRS). Based in Mannheim and Kiel, they will add 120 beds to hVIVO’s facilities and expand its ability to conduct early-stage clinical trials. More at #Proactive #ProactiveInvestors http://ow.ly/OoHq105Ya0r

FUJIFILM Irvine Scientific sells its medical media business to Astorg  🤝💰 FUJIFILM Irvine Scientific, Inc., a leading global provider of cell culture solutions for the life science and medical markets, has announced an agreement to sell its Medical Media Business Unit to Astorg, a prominent pan-European private equity firm with an extensive track record in healthcare investments. This sounds like a significant development in the cell culture media market. Link in the comments for the full story. 🌐